Conversely, a small molecule inhibitor targeting IRE1α was shown to decrease c-MYC levels and inhibit growth of prostate cancer cells and tumors (50), demonstrating a regulatory feedback loop between XBP1 and c-MYC. Here, XBP1 is linked to prostate cancer.